Finally, it is suggested that PRMT5i de-represses expression of immune genes in AR + and AR − PCa cells, which provides rationale for combined PRMT5i and immunotherapy, especially in inhibiting CRPC [75]. The gene discussed is AR; the disease is posterior cortical atrophy.